Comments on The cost-effectiveness of bimatoprost, latanoprost and timolol in treatment of primary open angle glaucoma in five European countries.
Soto
Javier
J
D000577:Amides / Q000191:economics* / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000191:economics* / Q000627:therapeutic use; D000069580:Bimatoprost; D003008:Cloprostenol / Q000031:analogs & derivatives; D003362:Cost-Benefit Analysis; D005060:Europe; D005902:Glaucoma, Open-Angle / Q000188:drug therapy* / Q000191:economics; D006801:Humans; D000077338:Latanoprost; D008055:Lipids / Q000191:economics* / Q000627:therapeutic use; D011461:Prostaglandins F, Synthetic / Q000191:economics* / Q000627:therapeutic use; D013999:Timolol / Q000191:economics* / Q000627:therapeutic use
D000577:Amides; D000959:Antihypertensive Agents; D008055:Lipids; D011461:Prostaglandins F, Synthetic; D003008:Cloprostenol; D000077338:Latanoprost; D013999:Timolol; D000069580:Bimatoprost